$BWAY

Mitrany Rayten Michal Ety sold 10,000 shares of BWAY

Mitrany Rayten Michal Ety sold 10,000 shares of Brainsway Ltd. (BWAY) on 2026-05-25.

Original reporting
SEC EDGAR · Mitrany Rayten Michal Ety
Published May 26, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BWAY
Neutral
low confidence
Mentioned
$BWAY
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BWAYNeutralLow
01

Why it matters

The disclosure may slightly affect sentiment, but without disclosed transaction value or accompanying operational news, it is unlikely to drive a sustained repricing by itself.

02

Market read

Traders may monitor for follow-on insider activity or other catalysts, but this filing alone is not a strong fundamental signal.

03

What to watch

No 10b5-1 plan is stated, but the absence of disclosed price/proceeds prevents assessing whether the sale was at a favorable or unfavorable level versus recent trading.

Relevance 6/10Timing: Immediate (new SEC Form 4 disclosure dated 2026-05-26 for a 2026-05-25 sale).

Background

The article is an SEC Form 4 insider transaction filing for Brainsway Ltd. (BWAY).

Company-level read

Ticker impact

$BWAYNeutralLow confidence
Context

Brainsway director Mitrany Rayten Michal Ety sold 10,000 shares in an open-market transaction disclosed via SEC Form 4.

Expected impact

Likely limited near-term impact; any reaction would be modest unless accompanied by broader company-specific news.

Evidence & confidence

This is a routine insider transaction disclosure without disclosed proceeds or accompanying fundamental catalysts, so it is more of a sentiment/positioning datapoint than a definitive re-rating trigger.

Market effects

Minimal—single-company insider sale without additional sector/regulatory/company operational updates.

Minimal—no geographic or cross-border catalyst described.

Minimal—no deal, trial, or macro driver referenced.

Counterpoint

The sale may reflect diversification or personal liquidity needs rather than a bearish view, especially since only the sale size is provided without performance context.

Key entities

  • Brainsway Ltd.

    Subject of the SEC Form 4 insider sale; director sold 10,000 shares on 2026-05-25.

  • Mitrany Rayten Michal Ety

    Director who executed an open-market sale of 10,000 shares; holdings after transaction were 20,480 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BWAYMedAI 8/10

BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™

BrainsWay Ltd. (NASDAQ: BWAY) reported results from a pilot study on its Deep TMS™ technology in patients with depression and early-stage Alzheimer’s disease. The study showed an 83.3% response rate and 50% remission rate in depressive symptoms, with measurable changes in brain activity. The study was published in the Journal of Geriatric Psychiatry and Neurology.

$BWAYMedAI 8/10

Brainsway Q2 Earnings Call Highlights

BrainsWay (NASDAQ:BWAY) reported Q2 gross profit up 34% to $12.8M with gross margin at 75%. Management cited a 30% backlog increase and SWIFT reimbursement progress, estimating 57M US covered lives. CFO Ido Marom said operating cash flow was $6.3M and raised 2026 revenue guidance to $68M-$70M. The company is also discussing Neurolief’s ProlivRx soft launch.

$BWAYHighAI 9/10

BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights

BrainsWay Ltd. (NASDAQ, TASE: BWAY) reported Q2 2026 revenue up 35% to $17.1 million. Adjusted EBITDA more than doubled to $3.5 million (20% margin). Remaining performance obligations rose 30% to $80.4 million, and it shipped 125 Deep TMS systems (+42% YoY). The company raised FY2026 revenue guidance to $68-$70 million and Adjusted EBITDA to $13-$14 million.

$BWAYHigh

Brainsway Ltd. (BWAY): Financial results for Q2 2026

Brainsway Ltd. (BWAY) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights Record s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025 Adjusted EBITDA more than doubled year-over-year to $3.5 million, with margin expanding t